<DOC>
	<DOCNO>NCT02929251</DOCNO>
	<brief_summary>RUBI , first prospective randomize , head head study , compare Adalimumab either anakinra , tocilizumab refractory Non Infectious Uveitis ( NIU ) . There firm evidence randomize controlled trial directly address best biologic agent severe refractory NIU . NIU cause devastate visual loss 20 % legal blindness . Corticosteroids immunosuppressant fail demonstrate sustainable remission 70 % refractory/relapsing severe uveitis . The incidence blindness NIU dramatically reduce recent year use biologics , raise question whether compound use earlier treatment severe non infectious uveitis . Contrasting immunosuppressor , biotherapies act rapidly highly effective steroid 's spar thus prevent occurrence cataract and/or glaucoma . Despite strong rationale , compound yet approve uveitis , guarantee innovative nature study aim select drop arm evidence efficacy already exist .</brief_summary>
	<brief_title>Randomized Trial Comparing Efficacy Adalimumab , Anakinra Tocilizumab Non-infectious Refractory Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Provide write , informed consent prior performance study specific procedures 2 . Diagnosis noninfectious intermediate , posterior , panuveitis least one eye fulfil International Study Group Classification Criteria ( Standardization Uveitis Nomenclature [ SUN ] criterion ) posterior , pan uveitis confirm documented medical history 3 . Currently uncontrolled uveitic disease . Uncontrolled uveitic disease define fulfil two follow criterion Inclusion : Active inflammatory chorioretinal and/or inflammatory retinal vascular lesion OR Vitreous haze grade &gt; 1+ accord SUN National Eye Institute ( NEI ) Scoring Vitreous Haze 4 . Are receive prednisone ≥10 mg/day ( equivalent dose another corticosteroid ) least 1 systemic immunosuppressant , , . Are receive IFNalpha , To intolerant immunosuppressant 5 . Best correct visual acuity ( BCVA ) ETDRS 20/20 20/400 ( approximately 85 20 letter ) study eye 6 . Best correct visual acuity ( BCVA ) ETDRS 20/20 good fellow eye ( approximately 20 letter ) 7 . Stable dose two week prior inclusion topical corticosteroid and/or NSAIDs 8 . Male female , Age &gt; = 18 year Inclusion 9 . Weight 40 120 kg ( 88.2 264 lb ) Inclusion 10 . Chest Xray result ( posteroanterior lateral ) within 12 week prior Inclusion evidence active Tuberculosis , active infection , malignancy 11 . For female subject childbearing age , negative serum pregnancy test 12 . For subject reproductive potential , willingness use contraceptive measure adequate prevent subject subject 's partner become pregnant study . Adequate contraceptive measure include hormonal method use two cycle prior Screening ( e.g. , oral contraceptive pill , contraceptive patch , contraceptive vaginal ring ) , barrier method ( e.g. , contraceptive sponge , diaphragm use conjunction contraceptive foam jelly , condom use conjunction contraceptive foam jelly ) , intrauterine method ( IUD ) , sterilization ( e.g. , tubal ligation monogamous relationship vasectomize partner ) , abstinence . 1 . Infectious uveitis , masquerade syndrome , uveitis due cause non infectious uveitis disease ( idiopathic uveitis permit ) 2 . Isolated anterior uveitis 3 . Presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible 4 . Contraindication mydriasis either eye presence posterior synechiae study eye mydriasis inadequate posterior segment examination 5 . Intraocular pressure ≥ 25 mmHg Goldmann tonometry advance glaucoma ( e.g. , cuptodisc ratio &gt; 0.9 , split fixation visual field , need &gt; 3 intraocular pressure lower medication keep Intra Occular Pressure ( IOP ) &lt; 22 mmHg ) either eye 6 . Monocular patient 7 . Active tuberculosis history untreated tuberculosis 8 . Known positive syphilis serology , HIV antibody , hepatitis B surface antigen antinucleocapsid antibody hepatitis B virus , and/or hepatitis C antibody . 9 . History malignancy within 5 year prior Inclusion carcinoma situ cervix adequately treat , nonmetastatic squamous basal cell carcinoma skin . 10 . History severe allergic anaphylactic reaction monoclonal antibody 11 . Infectious disease : Fever infection require treatment antibiotic within 3 week prior Inclusion History recurrent infection predisposition infection 12 . Known immunodeficiency 13 . History multiple sclerosis and/or demyelinate disorder 14 . Laboratory value assess Inclusion : Hemoglobin &lt; 8g/dL White Blood Cell Count ( WBC ) &lt; 2.0 x 103/mm3 Platelet count &lt; 80 x 103/mm3 Glomerular filtration rate ( GFR ) &lt; 30ml/min . Transaminases &gt; 3 time upper normal value 15 . Use follow systemic treatment specify period : Any previous systemic biologic therapy Any prior treatment tocilizumab , anakinra , anti Tumor Necrosis Factor ( TNF ) Treatment systemic alkylating agent within 12 month prior Inclusion Inclusion Day 0 ( e.g. , cyclophosphamide , chlorambucil ) Any live ( attenuate ) vaccine within 3 month prior Inclusion ; recombinant kill virus vaccine permit . Live seasonal flu H1N1 vaccine permit ≥ 2 week prior Inclusion . 16 . Use follow ocular treatment specify period : Previous anti Vascular Endothelial Growth Factor ( VEGF ) intravitreal therapy within 3 month prior Inclusion , anticipate use study period Treatment dexamethasone intravitreal implant [ Ozurdex® ] ) within 6 month prior Inclusion Intravitreal corticosteroid within 3 month prior Inclusion . Previous Subtenon 's corticosteroid injection permit administer least 2 month prior Inclusion 17 . Stage III IV New York Heart Association ( NYHA ) cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>